Kincell Bio

About Kincell Bio

Kincell Bio operates as a contract development and manufacturing organization (CDMO) with a specific focus on the cell therapy sector. The company was established in 2023, spinning out of Inceptor Bio to address manufacturing challenges for early-stage innovators in the field. Kincell was launched with an initial $36 million in funding led by Kineticos Ventures. It has since secured an additional $22 million in a round led by NewSpring Capital and existing investor Kineticos Life Sciences, bringing its total funding to $58 million.

The company is led by a team of seasoned professionals. Mark Bamforth, the current CEO and Board Chair, is a serial entrepreneur who has previously founded, built, and sold three other CDMOs, including Brammer Bio and Arranta Bio. Bruce Thompson, the Founding CEO and current CTO, has over two decades of experience in CMC strategy and cell therapy manufacturing from roles at Resilience, Lyell Immunopharma, and Pfizer. The leadership is further strengthened by Shailesh Maingi, founder of Kineticos Ventures and Inceptor Bio, who serves as the former Board Chairman.

Kincell Bio's business model is centered on providing comprehensive services to streamline the path from research to clinical trials for its clients, which are typically early-stage biotech companies and academic spinouts. The company generates revenue by offering a suite of services that cover the entire product lifecycle, from early clinical development to pivotal supply and commercial launch. Its core services include analytical development, process development, CMC (Chemistry, Manufacturing, and Controls) consulting, and GMP (Good Manufacturing Practice) manufacturing. The company specializes in immune cell therapies such as autologous and allogeneic CAR-T, CAR-NK, and CAR-M programs. This client-centric approach provides a personalized and responsive partnership, acting as an extension of the client's own team.

To support its operations, Kincell began with a fully staffed facility in Gainesville, Florida, and has since expanded. In April 2024, the company acquired a 32,800-square-foot manufacturing facility in Research Triangle Park, North Carolina, to enhance its capacity for mid- to late-stage clinical studies. This strategic expansion allows Kincell to offer scalable and high-quality manufacturing solutions, addressing the significant demand within the cell and gene therapy market.